Evidence map›Paper›PMID 41021203›Full record

SynthesisInflammopharmacology2025

Efficacy and safety of Mirikizumab in the treatment of moderate to severe inflammatory bowel diseases: a systematic review and updated meta-analysis.

Joel Gabin Konlack Mekontso, Joseph Yvan Bena Nnang, Samuel G J Fodop, Bishoy I B Elkoumes, Guy Loic Nguefang Tchoukeu, Anifatou B Kortim, Ticha B T Tembi, Akil Olliverre, Jarin Prasa, John Trillo

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joel Gabin Konlack MekontsoNew York City Health and Hospitals, South Brooklyn Health, 2601 Ocean Parkway, Brooklyn, NY, 11235, USA. konlackj@nychhc.org.ORCID http://orcid.org/0000-0001-7913-2927
Joseph Yvan Bena NnangFaculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon.
Samuel G J FodopSchool of Health and Medical Sciences, Catholic University, Kumbo, Cameroon.
Bishoy I B ElkoumesNew York City Health and Hospitals, South Brooklyn Health, 2601 Ocean Parkway, Brooklyn, NY, 11235, USA.
Guy Loic Nguefang TchoukeuTexas Tech University Health Sciences Center, Odessa, TX, USA.
Anifatou B KortimFaculty of Health Sciences, University of Bamenda, Bamenda, Cameroon.
Ticha B T TembiHubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
Akil OlliverreNew York City Health and Hospitals, South Brooklyn Health, 2601 Ocean Parkway, Brooklyn, NY, 11235, USA.
Jarin PrasaNew York City Health and Hospitals, South Brooklyn Health, 2601 Ocean Parkway, Brooklyn, NY, 11235, USA.
John TrilloNew York City Health and Hospitals, South Brooklyn Health, 2601 Ocean Parkway, Brooklyn, NY, 11235, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsInflammatory bowel diseases (IBD) remain challenging to treat despite advances in biologic therapies. Mirikizumab, a selective anti-IL-23p19 monoclonal antibody, shows promise, but its efficacy and safety across IBD populations require a comprehensive evaluation.

methodsWe conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing Mirikizumab to placebo in moderate-to-severe IBD. We assessed clinical response, clinical remission, endoscopic remission, adverse events (AEs) and treatment discontinuation. We applied a random-effects model and calculated numbers needed to treat (NNT) and harm (NNH).

resultsWe included four RCTs (2380 patients). Mirikizumab significantly increased the likelihood of clinical response by 69% (61.0% vs. 36.6%; RR 1.69; 95% CI [1.35, 2.10]; p  <  0.00001; NNT = 4), clinical remission by 74% (37.1% vs. 20.0%; RR 1.74; 95% CI [1.50, 2.02]; p  <  0.00001; NNT = 7), and endoscopic remission by 92% (28.7% vs. 15.4%; RR 1.92; 95% CI [1.63, 2.27]; p  <  0.00001; NNT = 8). This efficacy extended to biologic-failed patients and across both IBD populations. Mirikizumab was safe, with reduced rates of serious AEs (5.2% vs. 9.1%; RR 0.53; 95% CI [0.41, 0.70]; p  <  0.00001; NNH = 24), treatment discontinuation (2.5% vs. 7.5%; RR 0.33; 95% CI [0.20, 0.56]; p  <  0.0001; NNH = 20), and IBD worsening (3.3% vs. 13%; RR 0.26; 95% CI [0.19, 0.36]; p  <  0.00001; NNT = 11).

conclusionMirikizumab significantly improves clinical and endoscopic outcomes in moderate-to-severe IBD, with consistent efficacy in biologic-refractory disease and a favorable safety profile, making it a valuable therapeutic option.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedGastrointestinal AgentsInflammatory Bowel DiseasesHumansRandomized Controlled Trials as TopicRemission InductionSeverity of Illness IndexTreatment OutcomeAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedGastrointestinal AgentsBiologic therapyCrohn’s diseaseInflammatory bowel diseasesMirikizumabUlcerative colitis

Identifiers

PMID41021203

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.